Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
In a recent High Court ruling, a mother lost a legal battle against her ex-husband regarding whether their 16-year-old daughter should be allowed to use gender-changing medications. The case highlights broader issues surrounding trans healthcare, including the use of puberty blocking drugs by UK teens, some of whom have resorted to the black market. Dr. Hilary Cass's review has brought to light the risks associated with these drugs, leading to legal actions by former patients of the Tavistock clinic against the NHS.
There is a mountain of confirmation by a half-dozen comprehensive evidence reviews that AAP is out on a limb on child sex changes. WPATH itself commissioned a review and suppressed it after it found no good evidence to support the practice. AAP is going to die on this hill. https://t.co/g5a9b0rsy4
1. The Endocrine Society and the American Academy of Pediatrics have released statements in response to the Cass Review, rejecting bans. They reject "banning evidence-based medical care based on misinformation." Subscribe to support my journalism. https://t.co/LEiplLyQ2x
📌One-month recap since the final Cass Report: More European countries have restricted youth medical transitions, with others heading in that direction—in stark contrast to U.S. medical bodies, which have doubled down on medical pathways for minors. Thread and Link Below⬇️ https://t.co/4JHkEDjqQG
